ANN ARBOR, Mich. - Esperion (NASDAQ: NASDAQ:ESPR) today announced its participation in the upcoming 2024 American College of Cardiology's Annual Scientific Session (ACC.24) in Atlanta, Georgia. The company is set to present three subgroup analyses from the CLEAR Outcomes trial, focusing on statin-intolerant women, Hispanic/Latinx patients, and patients with obesity.
The CLEAR Outcomes trial is part of Esperion's clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, which are designed to lower cholesterol levels in patients. The program aims to provide evidence on the safety and efficacy of bempedoic acid, a new ATP citrate lyase inhibitor.
The first presentation, led by Dr. Leslie Cho of the Cleveland Clinic, will discuss characteristics and outcomes for statin-intolerant women receiving bempedoic acid. This session is scheduled for 9:45 AM ET on April 6, 2024. The second, presented by Dr. Fatima Rodriguez of Stanford Medicine, will cover outcomes for statin-intolerant Hispanic/Latinx patients and is slated for 1:45 PM ET on the same day.
The final presentation, by Dr. Harold Bays from the Louisville Metabolic and Atherosclerosis Research Center, will examine the drug's impact on cardiovascular disease outcomes in patients with obesity, set for 1:15 PM ET on April 7, 2024.
In addition to these presentations, Esperion will participate in a moderated session discussing patient access to bempedoic acid therapy, an industry expert theatre, and will maintain a commercial and medical information booth throughout the event.
Dr. JoAnne Foody, Chief Medical Officer for Esperion, expressed the company's commitment to underserved populations and the importance of these subgroup analyses in contributing to the overall theme of ACC.24, which is "Cardiovascular Care for All."
Esperion's involvement in ACC.24 underscores their ongoing efforts to address unmet medical needs in cardiovascular and cardiometabolic diseases. The company's CLEAR clinical research program is anticipated to involve more than 60,000 participants by its conclusion.
The information regarding Esperion's participation in ACC.24 is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.